GlobeImmune - Top 20 VC deals of 2007

Company: GlobeImmune
Based: Louisville, CO
Amount: $41.16
Round: Third
Investors: Adams Street Partners, Allianz Private Equity Partners, Eminent Venture Capital, GC&H Partners
HealthCare Ventures, Lilly Ventures, Medica Venture Partners, Morgenthaler Ventures, Pac-Link Management Corporation, Sequel Venture Partners, Undisclosed Corporate Investor, Undisclosed Investor, Undisclosed Venture Firm, WRF Capital, Yasuda Enterprise Development

Scoop: GlobeImmune's researchers have been using recombinant yeast--Saccharomyces cerevisiae--that is genetically modified to express a protein that triggers a killer T cell response directed at diseased cells. These therapies are called Tarmogens. A Phase II trial for GI-4000, its pancreatic cancer drug, is currently underway. It's also preparing a separate trial for hepatitis C drug GI-5005-02. GlobeImmune was featured as one of FierceBiotech's Emerging Drug Developers.

More News:
GlobeImmune lands $41M venture round. Report

GlobeImmune - Top 20 VC deals of 2007
Read more on

Suggested Articles

The drug failed a futility analysis in March, but Biogen resurrected it after factoring in data generated after the cutoff for the interim assessment.

The negative top-line data deal a big blow to the prospects of a drug analysts tipped to achieve blockbuster sales if it cleared phase 3.

Intrepida Bio launched with $9.5 million from Sofinnova and Canaan Partners to develop anti-BAG3 antibodies for the treatment of cancer.